Condition: Treatment Resistant Depression · Sponsor: atai Therapeutics, Inc.
This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmucosal buccal film (VLS-01-BU) in patients with treatment resistant Major Depressive disorder (TRD) and will characterize the onset and durability of antidepressant effects of VLS-01-BU versus placebo.
This description comes directly from the study's public registry record.
Kevin Craig, MD · 332-282-0507 · clinicaltrials@atai.life
Always discuss trial participation with your own doctor first.
| Noble Clinical Research | Tucson, Arizona, United States | Recruiting |
| Pillar Clinical Research, LLC | Little Rock, Arkansas, United States | Recruiting |
| Preferred Research Partners, Inc. | Little Rock, Arkansas, United States | Recruiting |
| Woodland Research Northwest | Rogers, Arkansas, United States | Recruiting |
| CenExel | Garden Grove, California, United States | Recruiting |
| Behavioral Research Specialists, LLC | Glendale, California, United States | Recruiting |
| Kadima Neuropsychiatry Institute | La Jolla, California, United States | Recruiting |
| Collaborative Neuroscience Research, LLC | Los Alamitos, California, United States | Recruiting |
| TRIP Clinical at Psychedelic Science Institute | Santa Monica, California, United States | Recruiting |
| Mountain View Clinical Research Inc. | Denver, Colorado, United States | Recruiting |
| CenExel | Hollywood, Florida, United States | Recruiting |
| Bioresearch Partner | Miami, Florida, United States | Recruiting |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06524830